問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Shin Kong Memorial Wu Ho-Su Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 111Taipei CityShih Lin

Recruiting Trial

52Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

142Cases

2018-06-04 - 2020-01-19

Phase III

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

  • Condition/Disease

    Age-Related Macular Degeneration (AMD)

  • Test Drug

    Conbercept

Participate Sites
5Sites

Recruiting5Sites

2014-04-30 - 2017-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-01-04 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-09-01 - 2018-09-06

Phase III

SAPPHIRE: A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion

  • Condition/Disease

    subjects with retinal vein occlusion

  • Test Drug

    CLS-TA

Participate Sites
5Sites

Terminated4Sites

2011-04-01 - 2019-04-26

Phase III

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

  • Condition/Disease

    Atherosclerosis

  • Test Drug

    Canakinumab / ACZ885

Participate Sites
14Sites

Terminated14Sites

2012-07-01 - 2013-06-30

Phase III

A 14 week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 in comparison to olmesartan in elderly patients with essential hypertension

  • Condition/Disease

    Essential Hypertention

  • Test Drug

    LCZ696

Participate Sites
10Sites

Terminated10Sites

2008-08-01 - 2010-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-08-01 - 2022-03-31

Phase III

A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON)

  • Condition/Disease

    neovascular age-related macular degeneration (TALON)

  • Test Drug

    Brolucizumab (RTH258)

Participate Sites
4Sites

Recruiting4Sites

2021-01-07 - 2023-06-08

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2016-12-01 - 2018-12-31

Phase II

A Phase IIa, Randomized, Double blinded, Placebo-controlled, Dose-finding Study for Single-dose Administration of TLC599 in Patients with Osteoarthritis (OA) of Knee

  • Condition/Disease

    Osteoarthritis (OA) of Knee

  • Test Drug

    TLC599

Participate Sites
9Sites

Terminated8Sites

張棋楨
Taipei Medical University Hospital

1 11 12 13 14 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB